Psoriatic Arthritis Patients Play A Substantial Role in Biologic Switching Decisions. Cimzia and Otezla Benefit Most From Patient Involvement, According to Spherix Global Insights

ZUG, Switzerland, April 25, 2016 /PRNewswire/ -- A recent survey conducted by Spherix Global Insights reveals that psoriatic arthritis (PsA) patients play an important role in the decision to switch to - and from - biologics/Otezla.  Specifically, the RealWorld Dynamix™: Biologic & Otezla Switching in Psoriatic Arthritis report finds that in two-thirds of patients who have recently switched brands, the patient was either the primary driver for the switch or had significant input.  Furthermore, treating rheumatologists report that in one-third of cases where the patient was the primary driver in the decision, there was no clinical rationale to make the switch. 

UCB's Cimzia (certolizumab) and Celgene's Otezla (apremilast) benefit the most when patients are the driving force behind PsA biologic switches. Physicians reported that patient preference was a driver in over one in six of their recent decisions to switch to Cimzia and Otezla.  Conversely, PsA patients are least likely to be involved in switches that result in treatment with Janssen's Stelara (ustekinumab) or Remicade (infliximab).

According to Robbie McCarthy, VP Immunology, Rare Disease & Patient Portfolio at Spherix Global Insights, "Patient education on biologic treatment choices becomes increasingly important when the patient base, such as we are seeing in PsA, actively participates in treatment decisions."

Surveyed rheumatologists in the study also reveal that one-quarter of their PsA patients treated with biologics or Otezla will switch brands in a given year. Outside of patient influence, the most common drivers behind the decision to switch from a specific biologic/Otezla treatment involve arthritis and skin related efficacy issues. Further biologic and Otezla switching dynamics are covered in depth in RealWorld Dynamix™: Biologic & Otezla Switching in Psoriatic Arthritis, which includes data from 200 surveyed U.S. rheumatologists and analysis of nearly 1000 de-identified psoriatic arthritis (PsA) patient records.

About Spherix Global Insights 
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Zug, Switzerland with US offices in Cambridge, MA. We specialize in renal, autoimmune, neurologic and rare disease markets. 

For more information: 
Dan Cassidy, Business Development
Telephone:  +1-610-324-3164 
[email protected] 
www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Related Links

http://www.spherixglobalinsights.com